While the expanded approval fulfills an unmet meet in postmenopausal women, its benefits are marginal in that population.
The FDA approved Addyi (flibanserin), a libido-enhancing drug, in postmenopausal women under the age of 65. Experts explain ...
Newsworthy Women on MSN
New FDA move targets long-ignored menopause health issue
On December 15, 2025, the U.S. Food and Drug Administration approved the medication Addyi for the treatment of hypoactive ...
Menopause doesn`t end your sex life! Discover how desire changes and reclaim intimacy with solutions for a fulfilling `Second Spring`. Click for expert insights.
As the year comes to a close, we revisit some of the top Urology Times podcast episodes from 2025. Joshua Palka, DO, reflects on the key trends that shaped urologic oncology in 2025, emphasizing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback